PATHOMORPHOLOGICAL FACTORS OF THE RECURRENCE PROGNOSIS FOR LOCALLY–SPREAD PROSTATIC CANCER AFTER RADICAL PROSTATECTOMY

Keywords: locally–spread prostatic cancer; biochemical recurrence; pathomorphological factors of prognosis

Abstract

Objective. Pathomorphological factors of the recurrence prognosis for clinically verified locally–spread prostatic cancer after radical prostatectomy were analysed.

Маterials and methods. The impact of unfavorable pathomorphological factors on the biochemical recurrence occurrence in 106 patients, suffering locally–spread prostatic cancer, was studied.

Results. In 55 (51.9%) patients the prostatic cancer recurrence was revealed. Positive surgical edge was noted in 34.9% of observations, perineural tumoral invasion – in 49.1%, metastases in regional lymphatic nodes – in 19.8%, the Gleason index value 8 points and more – in 25.5%; in 25.5% – the only one, in 23.6% – two, in 13.2% – three, and in 4.7% – all four factors were revealed. While absence of unfavorable factors the recurrence have occurred in 14.3% patients.

Conclusion. While enhancement of the unfavorable pathomorphological factors quantity in patients, suffering clinically verified locally–spread prostatic cancer, the recurrence occurrence risk is statistically trustworthily raising.

Author Biographies

V. М. Grygorenko, Іnstitute of Urology, Kyiv

Viacheslav Grygorenko, MD, PhD; Institute of Urology, Kyiv, Ukraine,

department of reconstructive urology and new technologies, chief of department;

9–A, V.Vynnychenko str., 04053, Kyiv, Ukraine;

 +38 (044) 486–67–31;

email: grygorenkosl@gmail.com

М. V. Vikarchuk, Іnstitute of Urology, Kyiv

Mark Vikarchuk; Institute of Urolog,

 Kyiv, Ukraine, department of reconstructive urology and new technologies, urologist;

9–A, V.Vynnychenko str., 04053, Kyiv, Ukraine;

+38 (044) 486–67–31;

 email: vikarchuk@email.ua;

R. О. Danylets, Іnstitute of Urology, Kyiv

Rostyslav Danylets, PhD;

Institute of Urology,

 Kyiv, Ukraine, department of reconstructive urology and new technologies, urologist, senior resarcher

;9–A, V.Vynnychenko str., 04053, Kyiv, Ukraine;

+38 (044) 486–67–31;

email: danyletsmd@gmail.com

Yu. М. Bondarenko, Іnstitute of Urology, Kyiv

Yuriy Bondarenko, PhD;

Institute of Urology, Kyiv, Ukraine,

department of urolithias, urologist, senior resarcher;

9–A, V.Vynnychenko str., 04053, Kyiv, Ukraine; +38 (044) 486–67–31;

email: b.yuriy.m@gmail.com

V. О. Rudakov, Іnstitute of Urology, Kyiv

Valerii Rudakov;

Institute of Urology, Ukraine", Kyiv, Ukraine,

polyclinic department, chief of department;

9–A, V.Vynnychenko str., 04053, Kyiv, Ukraine;

+38 (044) 486–67–31;

email: varudakov@gmail.com

References

1. Arnold M, Karim–Kos HE, Coebergh JW, Byrnes G, Antilla A, Ferlay J, et al. Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory. Eur J Cancer. 2015 Jun;51(9):1164–87.

2. Gnanapragasam VJ, Mason MD, Shaw GL, Neal DE. The role of surgery in high–risk localised prostate cancer. Br J Urol Int. 2012;109(5):648–58.

3. Loeb S, Smith ND, Roehl KA, Catalona WJ. Intermediate–term potency, continence, and survival outcomes of radical prostatectomy for clinically high–risk or locally advanced prostate cancer. Urology. 2007;69:1170–5.

4. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate–cancer survivors. New Engl J Med. 2008;358:1250–61.

5. Yossepowitch O, Eggener SE, Serio AM, Carver BS, Bianco FJ Jr, Scardino PT, et al. Secondary therapy, metastatic progression, and cancer–specific mortality in men with clinically high–risk prostate cancer treated with radical prostatectomy. Eur Urol. 2008;53:950–9.

6. Carver BS, Bianco FJ Jr, Scardino PT, Eastham JA. Long–term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol. 2006;176:564–8.

7. Xylinas E, Daché A, Rouprêt M. Is radical prostatectomy a viable therapeutic option in clinically locally advanced (cT3) prostate cancer? Br J Urol Int. 2010;106(11):1596–600.

8. Daly T, Hickey BE, Lehman M, Francis DP, See AM. Adjuvant radiotherapy following radical prostatectomy for prostate cancer. Cochrane Database Syst Rev. 2011:CD007234.

9. Briganti A, Karnes RJ, Da Pozzo LF, Cozzarini C, Capitanio U, Gallina A, et al. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2–4 pNb prostate cancer: results of a matched analysis. Eur Urol. 2011;59:832–40.

10. Sobin LH, Gospodarowicz MK, Wittekind Ch. International Union against Cancer.7th ed. 2009. Chichester, West Sussex, UK; Hoboken, NJ : Wiley–Blackwell; 2010:310 р.
Published
2017-12-20
Section
General Problems of Surgery